Adlai Nortye Ltd ADR Dossier
Qualitative Analysis
Business overview
Adlai Nortye Ltd. (Nasdaq: ANL) is a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative, targeted, and immune-modulating cancer therapies. The company maintains a dual research and development presence in both the United States (North Brunswick, New Jersey) and China (Hangzhou). Following the termination of its Phase 3 trial for its former lead candidate Buparlisib (AN2025) due to futility and toxicity concerns, Adlai Nortye has strategically pivoted and refocused its pipeline toward earlier-stage assets. Its current pipeline is anchored by AN9025, an orally bioavailable pan-RAS(ON) inhibitor designed to target a broad spectrum of RAS mutations, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload. Other active programs include Palupiprant (AN0025), an oral EP4 antagonist being evaluated in Phase 2 trials for rectal cancer, and AN4005, an oral small-molecule PD-L1 inhibitor.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the clinical failure of flagship candidate buparlisib (AN2025) in May 2025, the company terminated the program and refocused its R&D resources on earlier-stage, high-potential assets, specifically next-generation cancer immunotherapies (AN8025, AN4005) and RAS-targeting therapies (AN9025, AN4035).
Expected impact: Extends operational runway and shifts company focus toward proprietary, high-barrier frontier innovations.
Securing substantial private placement equity financings (PIPE) to shore up the balance sheet and fund the refocused clinical pipeline through advanced milestones.
Expected impact: Provides a significantly longer operational runway to generate clinical data for early-stage oncology assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants ASK Pharm exclusive rights to develop, manufacture, and commercialize the proprietary pan-RAS(ON) inhibitor AN9025 in mainland China, Hong Kong, and Macao, while Adlai Nortye retains worldwide rights outside the territory.
Terms: Total consideration of up to RMB 1.6 billion (approx. USD 230 million), including an upfront payment and near-term milestones exceeding USD 20 million, plus tiered royalties ranging from high single-digit to mid-teens percentage of net sales.
Nippon Kayaku holds first proposal rights to opt into two additional early-stage programs from Adlai Nortye's pipeline (including AN4005, AN8025, and AN9025) for the Japan territory.
Terms: Subject to individual opt-in terms; initially established alongside a concurrent private placement during Adlai Nortye's IPO.